Direct AMPK Activation Confers Mutation‐Independent Therapeutic Benefit in Duchenne Muscular Dystrophy
Authors:
Open Access
- 4 February 2026
- journal article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (1) , e70200
Abstract
Background: Duchenne muscular dystrophy (DMD) is a severe, life‐limiting neuromuscular disorder (NMD) characterized by progressive muscle wasting and mitochondrial dysfunction. Although gene therapies offer promise, even those already approved by regulatory agencies, their use remains constrained by mutation specificity, delivery challenges and durability. Pharmacologically targeting AMPK has shown potential to ameliorate dystrophic pathology, but prior strategies have been hindered by inadequate efficacy and off‐target effects. Methods: Comparative transcriptomic analyses were conducted to assess concordance between gene expression profiles induced by direct AMPK activation and those observed in DMD patient muscle. To evaluate the therapeutic potential of sustained AMPK activation, DBA/2J‐mdx (D2.mdx; n = 8–10) mice were treated daily with MK‐8722 (MK; 5 mg·kg −1 ) or vehicle for 7 weeks, with healthy DBA/2J mice serving as controls. Additionally, DMD patient‐derived myotubes ( n = 4) were treated with MK (1 μM, 24 h) to assess AMPK‐mediated cellular adaptations in human cells. Results: Transcriptomic profiling revealed that MK modulated 206 DMD‐associated transcripts, reversing expression of 73 upregulated and 133 downregulated genes. In vivo, MK‐treated D2.mdx mice showed enhanced AMPK signalling (ACC phosphorylation, +120%–150%; p < 0.05), increased Ppargc1a expression (+60%, p < 0.05) and reduced inflammation‐ and fibrosis‐associated transcripts (−25%–50%; p < 0.05). Seven weeks of daily MK treatment enhanced (+95%; p < 0.05) whole‐body lipid oxidation during active periods without affecting energy expenditure or activity. Notably, we observed that repeated MK dosing did not adversely impact cardiac morphology or function ( p > 0.05). MK‐treated D2.mdx mice demonstrated improved grip strength fatigability (−35%, p < 0.05), inverted hang performance (+100%, p < 0.05) and treadmill exercise capacity (+20%, p < 0.05). Additional ex vivo muscle assessments revealed (+30%; p < 0.05) greater peak isometric force and improved twitch contractile kinetics. These functional adaptations were coincident with reduced myofibre damage and fibrosis, with increased sarcolemmal expression of utrophin, γ‐sarcoglycan and β‐dystroglycan (+10%–70%; p < 0.05), despite no changes in fibre size or mass. Mitochondrial assessments showed increased State III respiration (+80%; p < 0.05), reduced reactive oxygen species production (−70%; p < 0.05) and elevated OXPHOS protein content (+25%–45%; p < 0.05). In patient‐derived myotubes, MK similarly activated AMPK signalling, increased mitochondrial electron transport chain proteins (+25%–35%; p < 0.05) and enhanced maximal oxygen consumption (+50%–80%; p < 0.05) in DMDΔ44 and DMDΔ45 lines. Conclusions: These findings demonstrate that sustained, systemic activation of AMPK safely improves muscle function, metabolic health and dystrophic pathology in a mutation‐independent manner. This supports the therapeutic potential of direct AMPK agonists as a disease‐modifying strategy for DMD and other neuromuscular disorders.Keywords
Funding Information
- Canadian Institutes of Health Research (408289)
This publication has 42 references indexed in Scilit:
- Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axisAmerican Journal of Physiology-Cell Physiology, 2014
- The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targetsThe FASEB Journal, 2013
- AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophyTrends in Molecular Medicine, 2013
- Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophyClinical Nutrition, 2013
- AMPK Activation Stimulates Autophagy and Ameliorates Muscular Dystrophy in the mdx Mouse DiaphragmThe American Journal of Pathology, 2012
- Chronic AMPK stimulation attenuates adaptive signaling in dystrophic skeletal muscleAmerican Journal of Physiology-Cell Physiology, 2012
- Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscleHuman Molecular Genetics, 2011
- Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategiesPharmacology & Therapeutics, 2010
- AMPK in Health and DiseasePhysiological Reviews, 2009
- Population frequencies of inherited neuromuscular diseases—A world surveyNeuromuscular Disorders, 1991